Astec LifeSciences reports Q1 FY27 consolidated total income of ₹84.3 Cr, down 8%. The company achieved EBITDA breakeven (₹0.1 Cr) from a ₹10.5 Cr loss, driven by improved margins and capacity utilization.

Astec LifeSciences LimitedASTEC · Filed with the exchange

Enterprise Products revenue grew 42%, while CDMO fell 42% against a high base.

No comments yet. Be the first.

More from Astec LifeSciences Limited

Free

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

No card needed. Takes about a minute.